相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts
Tamara Perez-Jeldres et al.
INFLAMMATORY BOWEL DISEASES (2019)
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
A Case Series on Patients on Tofacitinib in Combination With a Biologic
Nashla S. Barroso et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2018)
Review article: novel oral-targeted therapies in inflammatory bowel disease
J. R. White et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease
Amy Hemperly et al.
INFLAMMATORY BOWEL DISEASES (2018)
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
Uma Mahadevan et al.
INFLAMMATORY BOWEL DISEASES (2018)
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
Bruce E. Sands et al.
JOURNAL OF CROHNS & COLITIS (2018)
Amelioration of colitis through blocking lymphocytes entry to Peyer's patches by sphingosine-1-phosphate lyase inhibitor
Kazuhiko Shirakabe et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
Wagner Ricardo Montor et al.
MOLECULAR CANCER (2018)
Progressive multifocal leukoencephalopathy after fingolimod treatment
Joseph R. Berger et al.
NEUROLOGY (2018)
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
Andrea Huwiler et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis
Eun Ha Kang et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis
Hui Zhang et al.
CIRCULATION (2018)
Targeting JAK-STAT signal transduction in IBD
Christoffer Soendergaard et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Stanley Cohen et al.
RHEUMATOLOGY AND THERAPY (2018)
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors
Abril Verden et al.
DRUG SAFETY (2018)
Next generation of small molecules in inflammatory bowel disease
Pablo Olivera et al.
GUT (2017)
New treatment strategies for ulcerative colitis
Julian Panes et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
JAK inhibition in inflammatory bowel disease
Pablo Olivera et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
SAFETY AND EFFICACY OF ABT-494 (UPADACITINIB), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM CELEST
William J. Sandborn et al.
GASTROENTEROLOGY (2017)
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease
Brigid S. Boland et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2017)
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Julian Panes et al.
GUT (2017)
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Lucy Y. Liu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
Frederic Vanhoutte et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Frontiers in Drug Research and Development for Inflammatory Bowel Disease
Diego Curro et al.
FRONTIERS IN PHARMACOLOGY (2017)
Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects
Mathurin Flamant et al.
DRUGS (2017)
Modulation of sphingosine-1-phosphate in inflammatory bowel disease
Laurent Peyrin-Biroulet et al.
AUTOIMMUNITY REVIEWS (2017)
Mechanisms and consequences of Jak-STAT signaling in the immune system
Alejandro V. Villarino et al.
NATURE IMMUNOLOGY (2017)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)
Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery
Soo-Jin Park et al.
BIOMOLECULES & THERAPEUTICS (2017)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans
Wei-Ching Huang et al.
FASEB JOURNAL (2016)
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Altered STAT4 Isoform Expression in Patients with Inflammatory Bowel Disease
Rukhsana Jabeen et al.
INFLAMMATORY BOWEL DISEASES (2015)
Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases
Andres J. Yarur et al.
INFLAMMATORY BOWEL DISEASES (2015)
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Lauren L. Levy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Small molecule drugs with immunomodulatory effects in cancer
Adrian G. Murphy et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
Christina Charles-Schoeman et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Mechanisms of Jak/STAT Signaling in Immunity and Disease
Alejandro V. Villarino et al.
JOURNAL OF IMMUNOLOGY (2015)
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs
Emilie Begagne et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Inhibiting Janus kinases to treat alopecia areata
Sherrie J. Divito et al.
NATURE MEDICINE (2014)
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Thorsten Hornung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
Leeyen Hsu et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans
Martin E. Dowty et al.
DRUG METABOLISM AND DISPOSITION (2014)
S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity
David C. Montrose et al.
JOURNAL OF LIPID RESEARCH (2013)
Therapeutic modulators of STAT signalling for human diseases
Gabriella Miklossy et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Fingolimod for Multiple Sclerosis
Daniel Pelletier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pharmacologic Evaluation of Sulfasalazine, FTY720, and Anti-IL-12/23p40 in a TNBS-Induced Crohn's Disease Model
Zaher A. Radi et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
Asher Kornbluth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
The transcription factors STAT5A/B regulate GM-CSF-mediated granulopoiesis
Akiko Kimura et al.
BLOOD (2009)
The effects of IL-6 on CD4 T cell responses
Oliver Dienz et al.
CLINICAL IMMUNOLOGY (2009)
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis
Ashley J. Snider et al.
FASEB JOURNAL (2009)
Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases
Xiaoyu Hu et al.
IMMUNITY (2009)
MECHANISMS OF DISEASE Inflammatory Bowel Disease
Clara Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
FTY720 (fingolimod) for relapsing multiple sclerosis
Alejandro Horga et al.
Expert Review of Neurotherapeutics (2008)
IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways
Liang Zhou et al.
NATURE IMMUNOLOGY (2007)
FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells
Carolin Daniel et al.
JOURNAL OF IMMUNOLOGY (2007)
Structural and functional characteristics of S1P receptors
T Sanchez et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis
T Mizushima et al.
INFLAMMATORY BOWEL DISEASES (2004)
The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α
BJ Pettus et al.
FASEB JOURNAL (2003)
分享论文
